ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Assessment of permanent impairment due to asthma[1]

Assessment of permanent impairment due to asthma[1]
Class Class 0 Class 1 Class 2 Class 3 Class 4
Whole person impairment rating (%) 0 2 to 10 11 to 23 24 to 40 45 to 65
Severity grade
Percent impairment   2 4 6 8 10 11 14 17 20 23 24 28 32 36 40 45 50 55 60 65
Grade   A B C D E A B C D E A B C D E A B C D E
Minimal Mild Moderate Severe
Clinical parameters (minimum medication need, frequency of attacks, etc) No medication required Occasional bronchodilator use (not daily use) Daily low-dose inhaled glucocorticoid (<500 mcg per day of beclomethasone or equivalent)

Daily medium or high-dose inhaled glucocorticoids (500 to 1000 mcg of beclomethasone or equivalent per day) and/or short periods of systemic glucocorticoids and a long acting bronchodilator

Daily use of glucocorticoids, systemic and inhaled, and daily use of maximum bronchodilators		 Asthma not controlled by treatment
Maximum postbronchodilator FEV1 percentage predicted* >80 70 to 80 60 to 69 50 to 59 <50
Objective tests for degree of airway hyperresponsiveness
PC20 mg/mL* 6 to 8 3 to 5 >0.5 to <3 0.25 to 0.5 0.125 to 0.24
FEV1: forced expiratory volume in one second; PC20: provocative dose of methacholine that results in a 20% decrease in forced expiratory volume in one second.
* The "key" factor PC20 indicates and measures the degree of airway hyperresponsiveness. Alternatively the postbronchodilator FEV1 percentage predicted is used as key factor.
¶ Percent predicted FEV1 after albuterol therapy.
References:
  1. Modified from Ranavaya MI. The challenge of evaluating asthma impairment and disability. AMA Guides Newsletter. May-June 1997: 1-4.
Reprinted from AMA's Guides to the Evaluation of Impairment, 6th Edition with the permission of the American Medical Association, Copyright © 2008. All Rights Reserved.
Graphic 95322 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟